Business News • PR NewsWire • NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

NORGINE B.V. and KOREA PHARMA CO., LTD. Enter Into Exclusive Licence Agreement for the Commercialisation of PLENVU® in the Republic of Korea

AMSTERDAM and SEOUL, South Korea, January 3, 2019 /PRNewswire/ -- Norgine to receive a significant upfront payment and undisclosed sums in sales milestones along with double-digit percentage royalties Norgine retains full commercial rights to PLENVU® in all unlicensed countries NORGINE...

View More : https://www.prnewswire.com:443/news-releases/norgine-b-v-and-korea-pharma-co-ltd-enter-into-exclusive-licence-agreement-...

Releted News by prnewswire

Gathering Hotspots of the Preparation Industry, In Step with the International Pharmaceutical Trends

China Daily app launches Global Edition

HomeAid America Names Sheryl Palmer 2019-2020 Chairman